Lundbeck is a global pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
More information about Lundbeck
According to the World Health Organization, WHO, more than 700 million cases of brain diseases are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives.
As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics.
Research and development
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ more than 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back around 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from brain diseases.
More information about developing drugs
Lundbeck markets a number of different pharmaceuticals for the treatment of brain diseases. The most recently launched compounds include: Brintellix® (depression), Cipralex/Lexapro® (depression), Abilify Maintena® (schizophrenia), Selincro® (alcohol dependence), Azilect® (Parkinson’s disease), Xenazine® (chorea associated with Huntington's disease), Sabril® (epilepsy) and Onfi® (Lennox-Gastaut syndrome).
More information about products
Lundbeck employs approximately 6,000 people worldwide, 2,000 of whom are based in Denmark. We have employees in 57 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark, China and the US. Lundbeck generated revenue of approximately DKK 15.3 billion in 2013.
Lundbeck’s Executive Management currently consists of two members and is temporarily being headed by Håkan Björklund, Chairman with extended operational responsibilities.
In 2013, 47% of our revenue derived from Europe, 17% from the USA and 27% from the International Markets region.
More information about markets (click the Revenue distribution tab)
Lundbeck was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Today we are among the biggest Danish companies.
In 1999, Lundbeck’s shares were listed on the Copenhagen Stock Exchange. The Lundbeck Foundation, which in 2012 distributed DKK 482 million in grants for various types of research each year, owns about 70% of the shares in Lundbeck, while the remaining 30% are traded on the stock exchange.
Get a quick overview of Lundbeck and our business.Download as PDF